Clinical Trial Update: Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism

View source ↗

Summary

This clinical trial update reports on anti-Xa activity in cancer patients receiving low-molecular-weight heparin for venous thromboembolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Venous Thromboembolism

Drugs mentioned

• Low molecular weight heparin (low molecular weight heparin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Neoplasms, Venous Thromboembolism | Status: UNKNOWN